Vanguard S&P 500 ETF vs Viatris Inc — how do they compare? Vanguard S&P 500 ETF trades at $687.68, while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while Vanguard S&P 500 ETF pays none, and Viatris Inc is trading nearer its 52-week high, Vanguard S&P 500 ETF nearer its low. Which is the better fit depends on your goals.
| VOO | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $698.29 | $17.39 |
52-Week Low | $571.45 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Trailing returns across standard periods
Latest headlines on both assets
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →